CGTLive®'s Weekly Rewind – August 30, 2024
CGTLive®’s Weekly Rewind covers FDA actions, research, and interviews in gene and cell therapies. Highlights include no FVIII-specific responses in hemophilia A patients, mouse research findings at ASGCT’s 2024 conference, Galpagos expanding its ATALANTA-1 trial to the US, NMPA’s decision based on the CARTIFAN-1 trial, and Dr. Mark Walters discussing gene therapy’s impact on treatment.
Related Clinical Trials
Highlighted Terms
Related News
CGTLive®’s Weekly Rewind covers FDA actions, research, and interviews in gene and cell therapies. Highlights include no FVIII-specific responses in hemophilia A patients, mouse research findings at ASGCT’s 2024 conference, Galpagos expanding its ATALANTA-1 trial to the US, NMPA’s decision based on the CARTIFAN-1 trial, and Dr. Mark Walters discussing gene therapy’s impact on treatment.